Julian Hickling

2.8k citations

30 papers · 2.3k indexed · h-index 20

Co-authors: Leszek K. Borysiewicz J. G. P. Sissons Shek Graham Sjoerd H. van der Burg Rienk Offringa Simon Stacey J St Clair Roberts Alison Fiander
Topics: Immunotherapy and Immune Responses (16 papers)Cervical Cancer and HPV Research (10 papers)Virus-based gene therapy research (6 papers)
Cited by: Immunology Epidemiology Virology
Journals: The Lancet The Journal of Experimental Medicine PLoS ONE
Partner nations: United Kingdom United States Switzerland

In The Last Decade

Julian Hickling

29 papers receiving 2.2k citations

Peers

Countries citing papers authored by Julian Hickling

Since Specialization

Citations

This map shows the geographic impact of Julian Hickling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julian Hickling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julian Hickling more than expected).

Fields of papers citing papers by Julian Hickling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julian Hickling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julian Hickling. The network helps show where Julian Hickling may publish in the future.

Co-authorship network of co-authors of Julian Hickling

This figure shows the co-authorship network connecting the top 25 collaborators of Julian Hickling. A scholar is included among the top collaborators of Julian Hickling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julian Hickling. Julian Hickling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial 2021 ·PLoS ONE ·Alexandra C. I. Depelsenaire,(unknown),(unknown),James W. Wells,Christopher D. Anderson,Jason D. Lickliter,Steve Rockman,Jesse Bodle,Peter Treasure,Julian Hickling,Germain J. P. Fernando,Angus H. Forster	12
2	A global collaboration to advance vaccine product innovations – The Vaccine Innovation Prioritisation Strategy 2021 ·Vaccine ·Debra Kristensen,Birgitte Giersing,Julian Hickling,(unknown),(unknown),Anna-Léa Kahn,Vivian Hsu,(unknown),(unknown)	14
3	Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial 2020 ·PLoS Medicine ·Angus H. Forster,(unknown),Alexandra C. I. Depelsenaire,(unknown),James W. Wells,Adam K. Wheatley,Melinda J. Pryor,Jason D. Lickliter,Barbara Francis,Steve Rockman,Jesse Bodle,Peter Treasure,Julian Hickling,Germain J. P. Fernando	68
4	Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017 2017 ·Vaccine ·Sami L. Gottlieb,Birgitte Giersing,Julian Hickling,Rebecca Jones,Carolyn Deal,David C. Kaslow	37
5	Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23–24 August 2016 2017 ·Vaccine ·Justin R. Ortiz,Julian Hickling,Rebecca Jones,Armen Donabedian,Othmar G. Engelhardt,Jacqueline M. Katz,Shabir A. Madhi,Kathleen M. Neuzil,Guus F. Rimmelzwaan,James F. Southern,David Spiro,Joachim Hombach	16
6	Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5–7 May 2014 2015 ·Vaccine ·Nancy J. Cox,Julian Hickling,Rebecca Jones,Guus F. Rimmelzwaan,Linda C. Lambert,John W. Boslego,Larisa Rudenko,(unknown),James S. Robertson,Joachim Hombach,Justin R. Ortiz	11
7	Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method 2010 ·Vaccine ·(unknown),Subhash V. Kapre,Akshay Goel,(unknown),(unknown),Julian Hickling,(unknown),Manjari Lal,(unknown),(unknown),Debra Kristensen	40
8	Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7) 2004 ·Vaccine ·Emma J. Davidson,(unknown),Peter Sehr,Michael Pawlita,Lucy J.C. Smyth,Deborah J. Burt,A. Tomlinson,Julian Hickling,HC Kitchener,Peter L. Stern	99
9	Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. 2003 ·PubMed ·Emma J. Davidson,Christopher M. Boswell,Peter Sehr,Michael Pawlita,A. Tomlinson,Rhona J. McVey,(unknown),J St Clair Roberts,Julian Hickling,Henry C Kitchener,Peter L. Stern	140
10	Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine 2002 ·Vaccine ·Annemieke de Jong,Terence W O’Neill,(unknown),Kitty M.C. Kwappenberg,Susan E. Chisholm,Nigel Whittle,(unknown),(unknown),J St Clair Roberts,Rienk Offringa,Sjoerd H. van der Burg,Julian Hickling	140
11	Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens 2001 ·Vaccine ·Sjoerd H. van der Burg,Kitty M.C. Kwappenberg,Terence W O’Neill,Remco M.P. Brandt,Cornelis J.M. Melief,Julian Hickling,Rienk Offringa	124
12	Measuring human T-lymphocyte function 1998 ·Expert Reviews in Molecular Medicine ·Julian Hickling	16
13	A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer 1996 ·The Lancet ·Leszek K. Borysiewicz,Alison Fiander,(unknown),Stephen Man,Gavin W. G. Wilkinson,D. Westmoreland,A. S. Evans,Malcolm Adams,Simon Stacey,M. E. G. Boursnell,Erica Rutherford,Julian Hickling,Stephen Inglis	426
14	Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A0201) motif. 1994 ·PubMed Central* ·Ian Tarpey,Simon Stacey,Julian Hickling,H Birley,Adrian Renton,Angus McIndoe,Daniel Davies	30
15	A method for rapid screening of recombinant proteins for recognition by T lymphocytes 1992 ·European Journal of Immunology ·Julian Hickling,(unknown),Bin Yuan,Jonathan B. Rothbard,Roland Bülow	5
16	Polyclonal in vitro proliferative responses from nonimmune donors to Plasmodium falciparum malaria antigens require UCHL1⁺ (memory) T cells* 1990 ·European Journal of Immunology ·(unknown),Julian Hickling,Geoffrey Targett,J. H. L. Playfair	56
17	Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity 1990 ·Journal of General Virology ·George Strang,Julian Hickling,G. Angus McIndoe,Kevin Howland,David M. Wilkinson,Hitoshi Ikeda,Jonathan B. Rothbard	67
18	Peptides recognized by class I restricted T cells also bind to MHC class II molecules 1990 ·International Immunology ·Julian Hickling,(unknown),Kevin Howland,Steven G. E. Marsh,Jonathan B. Rothbard	27
19	Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. 1988 ·The Journal of Experimental Medicine ·Leszek K. Borysiewicz,Julian Hickling,Shek Graham,John Sinclair,Martin Cranage,Geoffrey L. Smith,J. G. P. Sissons	217
20	Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity 1988 ·European Journal of Immunology ·Leszek K. Borysiewicz,Shek Graham,Julian Hickling,Philip D. Mason,J. G. P. Sissons	104

About Julian Hickling

Julian Hickling is a scholar working on Immunology, Epidemiology and Health, having authored 30 papers that have together received 2.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (16 papers), Cervical Cancer and HPV Research (10 papers) and Virus-based gene therapy research (6 papers). The work is most often cited by research in Immunology (1.4k citations), Epidemiology (1.6k citations) and Virology (152 citations). Julian Hickling has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Leszek K. Borysiewicz, J. G. P. Sissons, Shek Graham, Sjoerd H. van der Burg, Rienk Offringa, Simon Stacey, J St Clair Roberts, Alison Fiander, Stephen Man and Peter L. Stern. Their work appears in journals such as The Lancet, The Journal of Experimental Medicine and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact